Market Signal Briefing

Spot reserves hit new lows as ETH moves to private wallets and staking.

Published:
September 29, 2025 │ 11:48 AM GMT

Created by Kornelija Poderskytė from DailyCoin

Ethereum (ETH) could be gearing up for a major rally, as spot exchange reserves hit new lows, signaling growing investor confidence, analysts at CryptoQuant warn.

Investors moving ETH to private wallets and staking accounts are reducing sell-side liquidity, a pattern analysts interpret as a sign of market confidence.

Is ETH About to Boom? Reserves Are Dropping! So What’s the Missing Piece?

“During all this time, the price will swing. If price falls below the accumulating whales’ realized price (3rd image), it will be a buy/accumulate opportunity.” – By @cryptometugce pic.twitter.com/dnqQ0GEQyr

— CryptoQuant.com (@cryptoquant_com) September 29, 2025
Why ETH is Leaving ExchangesCryptoQuant identifies three reasons for outflows: transfers to self-custody or staking, new purchases moved immediately off exchanges, and occasional internal wallet adjustments. 

Sponsored

This shows trust in Ethereum but doesn’t automatically push prices higher.

Past cycles show that large outflows often precede rallies, but prices can remain flat when selling absorbs buying pressure.

As per CryptoQuant analysts, the missing piece is demand. If macroeconomic conditions remain favorable, such as rate cuts, slower quantitative tightening, and increased global money flow, ETH could be positioned for a long-term bullish trend, with dips offering opportunities for accumulation.

Pillows Weighs InMeanwhile, cryptocurrency analyst, investor, and key opinion leader Ted Pillows highlights that recent ETH gains were largely fueled by short positions closing.

He emphasizes that ETH must reclaim $4,250 for further upside, warning that failure to do so could see prices revisit the $3,600–$3,800 support range.

$ETH had a pump today, but mostly due to short positions getting closed.

For more upside, Ethereum needs to reclaim the $4,250 level.

If ETH fails to reclaim, it could drop towards the $3,600-$3,800 support level. pic.twitter.com/CT3UpRUHYs

— Ted (@TedPillows) September 29, 2025
Pillows is not long-term bearish, noting that Ethereum has rallied nearly 250% from its bottom, and a Ethereum correction should conclude in a few weeks. “After that, ETH will rally above $10,000,” he says, underscoring bullish potential once the correction ends.

Why This Matters Falling spot reserves signal growing confidence in Ethereum. If demand follows, current outflows could mark the foundation for a significant rally, offering accumulation opportunities for long-term investors.

Read DailyCoin’s most popular crypto news:

$467K Sale of Free Hyperliquid Hypurr NFT Stuns Market
US Regulators Scrutinize Stock Surges Ahead of Corporate Crypto Bets

People Also Ask:How do Ethereum outflows affect the market?

Outflows reduce sell-side liquidity on exchanges, which can signal investor confidence and potentially precede price rallies if demand rises.

Can Ethereum outflows predict price rallies?

Historically, large ETH outflows from exchanges sometimes precede rallies, but prices may stay flat if selling pressure absorbs new buying.

What factors influence Ethereum’s long-term price trend?

Macro conditions such as interest rates, quantitative easing/tightening, and global money flow, combined with investor demand, can shape ETH’s trajectory.

What is the difference between Ethereum supply on exchanges vs. total supply?

Exchange supply refers to ETH held on trading platforms, while total supply includes all ETH in circulation, including private wallets and staking.

Can Ethereum reach new all-time highs?

Potentially yes, but price depends on factors like investor demand, macroeconomic conditions, network adoption, and market sentiment.

This article is for information purposes only and should not be considered trading or investment advice. Nothing herein shall be construed as financial, legal, or tax advice. Trading forex, cryptocurrencies, and CFDs pose a considerable risk of loss.

The XRP Ledger is on the verge of a historic milestone, with the total ledger count set to surpass 100 million imminently.

Specifically, the count stands at approximately 99.1 million, having experienced steady growth in recent months, according to the latest on-chain data retrieved by Finbold from CryptoQuant on September 29.

XRP Ledger count. Source: CryptoQuant
The ledger count has steadily risen since late 2022, reflecting greater use of the XRP Ledger, with the growth closely tracking notable XRP price movements.

In this case, XRP traded below $0.40 for much of 2023 as the ledger count climbed. With network activity accelerating in 2024, XRP broke out from under $0.50 to above $2, marking one of its strongest rallies in years alongside rapid ledger growth. 

In 2025, the token has held a higher range between $2 and $3, with steady ledger expansion supporting stronger price stability. 

Overall, reaching 100 million ledgers will be a symbolic milestone, highlighting XRP’s resilience and adoption amid rising blockchain competition.

Meanwhile, as the ledger count rises, XRP continues to attract significant interest despite trading below $3. 

Notably, whale investors have accumulated approximately 120 million tokens over the past three days. At the same time, market participants are watching the Securities Exchange Commission for approval of pending spot XRP ETF applications, which is expected later next month.

XRP price analysis 
At press time, XRP was trading at $2.86 after rallying almost 3% in the past 24 hours, while gaining about 1.4% on the weekly timeframe.

XRP seven-day price chart. Source: Finbold
At the current valuation, XRP is just below its 50-day SMA of $2.96, suggesting mild short-term weakness. However, it remains comfortably above the 200-day SMA of $2.59, indicating that the broader bullish trend is intact.

On the other hand, the 14-day RSI at 45.95 points to neutral momentum, showing neither overbought nor oversold conditions. Overall, XRP appears to be consolidating, with price action balanced between short-term resistance and long-term support.

Featured image via Shutterstock

In brief
The meme coin trenches have seen a drop in trading volume with the rise of perpetual futures decentralized exchanges, such as Aster.
Data shows grass roots meme coins hitting a six-month low, while perp DEXs spike in volume.
However, seasoned veterans aren't too concerned as they believe that meme coins are "cyclical" and will rebound.
The trenches are taking a hit with the rise of perpetual futures trading.

Solana meme coin launchpads have hit a six-month low for bonding curve trading volumes, dipping below $1 billion. Data expert Adam Tehc says this is because attention is elsewhere, specifically on perp futures, but seasoned meme coin traders aren’t too worried about it.

On Sunday, according to Dune data, Solana meme coin launchpads recorded $89.7 million in daily bonding curve trading volume amid a $796.2 million week. That’s the lowest for a single day in three-months and the lowest for a week in over six-months, according to a Tehc dashboard.

What is a bonding curve?The bonding curve refers to meme coin trading before the token graduates from the launchpad; for Pump.fun this takes place once a meme coin launched on the platform reaches a market cap of $66,000. As such, bonding curve trading volume acts as a measure of grassroots meme coin trading, rather than the buying and selling of established tokens like Fartcoin.

“Returns and attention are elsewhere right now,” Tehc told Decrypt. “Last week's perp decentralized exchange trend seems to have affected meme volumes particularly hard.”

This is reflected in the Dune data too, with perp trading volume skyrocketing to $466.8 billion last week—a 200% increase from $155.1 billion the week before. Meanwhile, Solana launchpad trading volume dropped 42% week-on-week from $1.36 billion to $796.2 million.

It comes as multi-chain perp decentralized exchange Aster caught the attention of traders with its mouthwatering 1001x leverage option and vocal backing from Binance co-founder Changpeng “CZ” Zhao. As a result, Aster’s token soared 2,000% in its first seven days as traders pipped it to rival the popular perp exchange Hyperliquid.

Despite its recent surge, however, users of prediction market Myriad, launched by Decrypt's parent company DASTAN, remain cautious on Aster's prospects, placing just a 33% chance on it reaching $4 before November.

Degens drawn to perpsPerpetual futures allow traders to speculate on whether an asset’s price will go up or down—via what is called a short or long—without needing to own the underlying asset. On top of this, perp decentralized exchanges have become well-known for their heavy levels of leverage, which appears to have attracted degen meme coin traders.

“Traders are going back to perps because it allows them to place higher leverage bets,” Pump.fun livestreamer and trader Ediz told Decrypt. “Leverage allows you to trade with your $1,000 like it's worth $10,000 or $100,000. The risk is higher because of liquidation but degenerates do not care.”

Pseudonymous trader 0xWinged told Decrypt that many meme coin traders are sidelined from the Aster trade and are patiently waiting for volume to rotate back into the trenches. 0xWinged said that they “don’t think it matters” that volume is down, as meme coins are “cyclical” and traders will return to eventually.

Trench vets like 0xWinged believe this as they’ve seen the ebbs and flows of meme coins before. Six-months ago, for example, the trenches were in a dire state as meme coins attempted to recover from Solana’s more than 50% drop from its January all-time high.

“Memes took a big hit, we've since recovered a bit,” Tehc said, reflecting on the state of the trenches in March. “To be back there we'd need to see a sustained volume drop over several weeks, traders are just gambling elsewhere.”

That said, Ediz believes the trenches are fatigued after a long-summer of meme coin trading.

“The trenches are tired,” he told Decrypt. “People barely hold coins past a 2x anymore because of PTSD and trauma. The trenches are currently way too extractive, and there are way too many people on farming, bundling, multi-walleting, etc. The trenches have gotten greedy and the average retail traders are tired of it.”

While the vibes are down, meme coin degens haven’t lost all hope. On Myriad, predictors remain cautiously optimistic about PUMP's prospects, placing a 54% chance on the token pumping to $3 billion rather than dropping to $1 billion—suggesting an underlying faith in its ecosystem.

As 0xWinged said, there are periods where meme coin volumes cool off, as traders look elsewhere for returns, and cleanse their pallets for degeneracy.

“I think volumes will return,” Tech said. "It will come back, I'm sure," 0xWinged added. "I need the trenches back."

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

NEW YORK and SEOUL, South Korea, Sept. 29, 2025 (GLOBE NEWSWIRE) -- K Wave Media (Nasdaq: KWM), a Korean cultural innovation and digital asset company, today announced plans to develop one of the industry’s first entertainment tokenization platforms. The platform will offer innovative tools such as revenue-sharing tokens that enable fractional ownership in films, concerts, branded content, and IP rights, along with smart contract–based automated royalty distribution to ensure transparent payouts to creators, investors, and rights holders.

Even ahead of its official launch, more than 37 leading Korean content producers and IP holders have signed MOUs to participate in and utilize the platform.

As part of this initiative, Galaxy Digital (Nasdaq/TSX: GLXY) — already serving as KWM’s Asset Manager and Strategic Advisor — made an approximately $1 million equity investment in KWM and received warrants for additional shares.

KWM seeks to transform how entertainment projects raise capital and how fans engage with their favorite stars and creative works. The platform will also accept Bitcoin as a means of payment and investment, positioning it at the forefront of digital finance in the entertainment sector.

“This platform is designed to be open and accessible. It’s not just for the 250 million+ global K-culture fans, but for anyone who wants to support and participate in entertainment IP and art,” said Ted Kim, CEO of KWM. “With a single click, fans can back the projects they love while enjoying a seamless, fun experience where the technology works in the background. The early commitment of 37 respected content and IP holders demonstrates the strong demand and confidence in what we’re building.”

KWM’s approach combines the global influence of Korean media, institutional-grade financial frameworks, and Web3 innovation — creating a new blueprint for public companies in the tokenization era.

With its cross-border strategy, KWM is uniquely positioned to connect Korean retail markets, U.S. institutional investors, and global crypto communities, creating a powerful multi-market growth engine.

This investment represents a significant milestone in KWM’s evolution and sets the stage for a new era of tokenized entertainment and borderless capital engagement.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”

“would,” “plan,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this communication and on the current expectations of KWM’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of KWM. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions.

If any of these risks materialize or KWM’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that KWM does not presently know, or that KWM currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect KWM’s current expectations, plans and forecasts of future events and views as of the date hereof. Nothing in this communication should be regarded as a representation by any person that the

forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and the risk factors of KWM described in KWM’s Form 20-F initially filed with the SEC on May 14, 2025, as amended, including those under “Risk
Factors” therein. KWM anticipates that subsequent events and developments will cause its assessments to change. However, while KWM may elect to update these forward-looking statements at some point in the future, KWM specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing KWM’s assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Media Contact:
Investor Relations: [email protected]
Evan Sneider: [email protected]

Highlights:

Three (3) drill holes from the 2025 drill program with strong analytical results are reported herein: CS25-036: nine (9) separate intervals, the widest being 272.5 m at 1.61% Li2O. CS25-038: 17 separate intervals, the widest being 66.5 m at 1.55% Li2O and
58.9 m at 1.09% Li2O.CS25-039: 12 separate intervals, including:108.5 m at 1.62% Li2O,71.0 m at 1.84% Li2O, 77.7 m at 1.48% Li2O, and107.4 m at 1.87% Li2O Three (3) drill rigs continue to operate on the Cisco Project, with a fourth scheduled to start at the end of October 2025. The upcoming drilling programs will be primarily focused on infill-scale drilling within the main mineralized zone, supporting the Company’s efforts to deliver an initial inferred Mineral Resource Estimate in the first half of 2026.
VANCOUVER, British Columbia, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Q2 Metals Corp. (TSX.V: QTWO | OTCQB: QUEXF | FSE: 458) (“Q2” or the “Company”) is pleased to report assay results from the ongoing 2025 drill program (the “2025 Drill Program”) at the Company’s Cisco Lithium Project (the “Project” or the “Cisco Project”), located within the greater Nemaska traditional territory of the Eeyou Istchee James Bay region of Quebec, Canada.

“Hole 36, with its 272.5 metres of continuous spodumene pegmatite grading 1.61% Li2O is a significant confirmation of the substantial width of the Mineralized Zone, especially when considered alongside intervals such as the 347 metres of continuous spodumene pegmatite in Hole 21,” said Neil McCallum, Vice President of Exploration for Q2 Metals. “Importantly, the Mineralized Zone remains open at depth and along strike, indicating strong potential for further expansion. Our geology team has designed a robust drilling program for the upcoming drilling program as we continue to define the extent of the Mineralized Zone and advance toward an inferred Mineral Resource estimate.”

The analytical results reported herein represent the first three (3) drill holes completed during the summer 2025 drill campaign.

As previously reported (see news release of June 10, 2025), hole CS25-036 was paused prior to the start of this year’s goose-hunting season break and ended before the intended completion depth. Several wide pegmatite intervals were intercepted, and assays were reported on the first 302 metres (“m”) of drilling completed during the winter 2025 drill campaign. The entirety of the assays on drill hole CS25-036 are now reported herein. The analytical results continue to confirm the robust width of the mineralized zone at this location.

Drill holes CS25-038 and 039 confirmed the mineralization at the southern portion of the mineralized zone with many intervals reporting greater than 1.5% Li2O. Drilling at the Cisco Project is ongoing, with three (3) drill rigs currently operating on site. A fourth drill rig has been mobilized to site and is scheduled to start at the end of October 2025, further accelerating the pace of the exploration program.

The primary focus of the fall and winter drilling campaign with be on infill-scale drilling within the main mineralized zone. The work is designed to support the Company’s objective of delivering an initial inferred Mineral Resource Estimate in the first half of 2026.

Pegmatite intervals and analytical results from the current program will be reported as they are received and reviewed.

Figure 1. Map of Recent Drill Holes with Analytical Results at Cisco Property

Figure 2. Cross-Section E, Hole-36 in relation to the Exploration Target

Table 1. Summary of Analytical Results of Drill Holes CS25-036, 038 and 039 at Cisco Project

All intervals of greater than 2 m of core-length and greater than 0.30% Li2O are included in Table 1. Internal dilution of non-pegmatite material was limited to intervals of less than 5 m. No specific grade cap or lower cut-offs were used during grade and width calculations. All intervals are reported as core widths and mineralized intervals in all the holes drilled thus far are not representative of the true width as the modelled pegmatite zones are being refined with every additional hole.

Drill Hole Collar Information

The summary of drill holes CS25-036, CS25-038 and CS-25-039, including basic location and dip/azimuth, is detailed below (Table 2).

Table 2. Summary of Drill Hole Collar Information, Cisco Project (CS25-036, CS25-038 and CS-25- 039)

Sampling, Analytical Methods and QA/QC Protocols

All drilling was conducted using diamond drill rig with NQ sized core and all drill core samples are shipped to SGS Canada’s preparation facility in Val D’Or, Quebec, for standard sample preparation (code PRP92) which includes drying at 105°C, crushing to 90% passing 2 mm, riffle split 500 g, and pulverize 85% passing 75 microns. The pulps are then shipped by air to SGS Canada’s laboratory in Burnaby, BC, where the samples are homogenized and subsequently analyzed for multi-element (including Li and Ta) using sodium peroxide fusion with ICP-AES/MS finish (code GE_ICM91A50). The reported Li grade will be multiplied by the standard conversion factor of 2.153 which results in an equivalent Li2O grade. Drill core was saw-cut with half-core sent for geochemical analysis and half-core remaining in the box for reference. The same side of the core was sampled to maintain representativeness.

A Quality Assurance / Quality Control (QA/QC) protocol following industry best practices was incorporated into the sampling program. Measures include the systematic insertion of quartz blanks and certified reference materials (CRMs) into sample batches at a rate of approximately 5% each. Additionally, analysis of pulp-split and reject-split duplicates was completed to assess analytical precision. The QP has verified the QA/QC results of the analytical work.

Qualified Person 

Neil McCallum, B.Sc., P.Geol, is a Qualified Person as defined by NI 43-101, and a registered permit holder with the Ordre des Géologues du Québec and member in good standing with the Professional Geoscientists of Ontario. Mr. McCallum has reviewed and approved the technical information in this news release. Mr. McCallum is a director and the Vice President Exploration for Q2. 

Upcoming Events 

Q2 is attending the following conferences and events: 

Investissement Quebec
Critical and Strategic Minerals Trade MissionSouth Korea & JapanSeptember 29 – October 3, 2025The Hidden Gems ConferenceNew York, NYOctober 20 – 21, 2025IMARCSydney, AustraliaOctober 21 – 23, 2025XPLORMontreal QCOctober 27 – 30, 2025    ABOUT Q2 METALS CORP. 

Q2 Metals is a Canadian mineral exploration company focused on the Cisco Lithium Project located within the greater Nemaska traditional territory of the Eeyou Istchee, James Bay, Quebec, Canada.

Cisco is comprised of 801 claims, totaling 41,253 hectares, with the main mineralized zone just 6.5 km from the Billy Diamond Highway, which transects the Project and leads to the Town of Matagami, rail head of the Canadian National Railway, approximately 150 km to the south.

The Cisco Project has district-scale potential with an initial Exploration Target estimating a range of potential lithium mineralization of 215 to 329 million tonnes at a grade ranging from 1.0 to 1.38% Li2O, based only on the first 40 holes drilled. An Exploration Target is used to provide a conceptual estimate of the potential quantity and grade of a mineral deposit, based on known and additional limited geological evidence. It is an early-stage assessment that will help to guide further exploration, but it is not a mineral resource or mineral reserve and should not be treated as such.

Drill testing continues with mineralization open at depth and along strike with potential for expansion at the Cisco Mineralized Zone. The 2025 Exploration Program is ongoing, with rolling assay results anticipated in the coming weeks and months as the Company works towards an initial mineral resource estimate. 

FOR FURTHER INFORMATION, PLEASE CONTACT: 

Alicia MilneJason McBrideChris AckermanPresident & CEOInvestor Relations ManagerCorporate [email protected]@[email protected]   Telephone:  1 (800) 482-7560 E-mail:[email protected]
www.Q2Metals.com  Social Media: 
Follow the Company: Twitter, LinkedIn, Facebook, and Instagram 

Forward-Looking Statements 

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian legislation. Forward-looking statements are typically identified by words such as: “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “would”, “will”, “potential”, “scheduled” or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Accordingly, all statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, any statements or plans regard the geological prospects of the Company’s properties and the future exploration endeavors of the Company. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions. 

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date specified in such statement. Forward looking statements in this news release include, but are not limited to, drilling results on the Cisco Project and inferences made therefrom, the conceptual nature of an exploration target on the Cisco Project, the potential scale of the Cisco Project, the focus of the Company’s current and future exploration and drill programs, the scale, scope and location of future exploration and drilling activities, the Company's expectations in connection with the projects and exploration programs being met, the Company’s objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, variations in ore grade or recovery rates, changes in project parameters as plans continue to be refined, unsuccessful exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, reallocation of proposed use of funds, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same. Readers are cautioned that mineral exploration and development of mines is an inherently risky business and accordingly, the actual events may differ materially from those projected in the forward-looking statements. Additional risk factors are discussed in the section entitled “Risk Factors” in the Company’s Management Discussion and Analysis for its recently completed fiscal period, which is available under Company’s SEDAR profile at www.sedarplus.com .   

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4331261e-cebb-4c67-9893-dbaaff9ac7d6

https://www.globenewswire.com/NewsRoom/AttachmentNg/3e4062bc-2cab-4b93-b874-008b2ac2b849

https://www.globenewswire.com/NewsRoom/AttachmentNg/e86ce834-9182-4102-b1e2-5bb67207ffe4

https://www.globenewswire.com/NewsRoom/AttachmentNg/7996190c-019b-4b46-81f9-74cb18b9498d

MALMÖ, Sweden, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Oatly Group AB (Nasdaq: OTLY), the world’s original and largest oat drink company, will report financial results for the third quarter ended September 30, 2025, on Wednesday, October 29, 2025, before the U.S. market opens. Oatly will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results.

The conference call and simultaneous live webcast can be accessed on Oatly’s Investors website at https://investors.oatly.com under “Events.” The webcast will be archived for 30 days.

About Oatly
We are the world’s original and largest oat drink company. For over 30 years, we have exclusively focused on developing expertise around oats: a global power crop with inherent properties. Our commitment to oats has resulted in core technical advancements that enabled us to unlock the breadth of the dairy portfolio, including alternatives to milks, ice cream, yogurt, cooking creams, spreads and on-the-go drinks. Headquartered in Malmö, Sweden, the Oatly brand is available in more than 50 countries globally.

For more information, please visit www.oatly.com.

September 29, 2025 07:00 ET

 | Source:

Forsys Metals Corp.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.

TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Forsys Metals Corp. (TSX: FSY) (FSE: F2T) (NSX: FSY) (“Forsys” or the “Company”)

Forsys is pleased to announce that it has entered into an agreement with Red Cloud Securities Inc. (“Red Cloud”), as sole underwriter and sole bookrunner, pursuant to which Red Cloud has agreed to purchase for resale on a “bought deal” basis, 17,858,000 units of the Company (the “Units”) at a price of C$0.56 per Unit (the “Offering Price”) for gross proceeds of C$10,000,480 (the “Underwritten Offering”).

Each Unit will consist of one class A common share of the Company (each, a “Unit Share”) and one-half of one class A common share purchase warrant (each whole warrant, a “Warrant”). Each whole Warrant shall entitle the holder to purchase one class A common share of the Company (each, a “Warrant Share”) at a price of C$0.80 at any time on or before that date which is 36 months after the Closing Date (as herein defined).

The Company will grant to Red Cloud an option, exercisable up to 48 hours prior to the Closing Date, to purchase for resale up to an additional 3,572,000 Units at the Offering Price for additional gross proceeds of up to C$2,000,320 (the “Over-Allotment Option”). The Underwritten Offering and the securities issuable upon exercise of the Over-Allotment Option shall be collectively referred to as the “Offering”.

The Company intends to use the net proceeds of the Offering to fund the advancement of the Company’s Norasa Project in Namibia and for working capital and general corporate purposes.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus Exemptions (“NI 45-106”), the Units under the Offering will be offered for sale to purchasers resident in the provinces of British Columbia, Alberta, Manitoba, Saskatchewan and Ontario (and, with the consent of the Company, in Québec) pursuant to the listed issuer financing exemption under Part 5A of NI 45-106, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “Listed Issuer Financing Exemption”). The Unit Shares and the Warrant Shares underlying the Units are expected to be immediately freely tradeable in accordance with applicable Canadian securities legislation if sold to purchasers resident in Canada under the Listed Issuer Financing Exemption. The Units may also be sold in offshore jurisdictions and in the United States on a private placement basis pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). All securities not issued pursuant to the Listed Issuer Financing Exemption will be subject to a hold period in accordance with applicable Canadian securities law, expiring four months and one day following the Closing Date.

There is an offering document (the “Offering Document”) related to the Offering that can be accessed under the Company’s profile at www.sedarplus.ca and on the Company’s website at www.forsysmetals.com. Prospective investors should read this Offering Document before making an investment decision.

The Offering is scheduled to close on October 16, 2025 (the “Closing Date”), or such other date as the Company and Red Cloud may agree. Completion of the Offering is subject to certain conditions including, but not limited to the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange.

The securities offered in the Offering have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Forsys Metals Corp.

Forsys Metals Corp. (TSX: FSY, FSE: F2T, NSX: FSY) is an emerging uranium developer focused on advancing its wholly owned Norasa Uranium Project, located in the politically and uranium-friendly jurisdiction of Namibia, Africa. The Norasa Uranium Project is comprised of the Valencia Uranium deposit (ML-149) and the nearby Namibplaas Uranium deposit (EPL-3638). Further information is available at the Company’s website at www.forsysmetals.com.

On behalf of the Board of Directors of Forsys Metals Corp. Richard Parkhouse, Investor Relations.

For additional information, please contact:

Pine van Wyk, Country Director, Forsys
email: [email protected]

Richard Parkhouse, Investor Relations
email: [email protected]  email: [email protected]

Forward Looking Statement

Certain information contained in this press release constitutes “forward-looking information”, within the meaning of Canadian legislation. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not exist”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur”, “be achieved”, or “has the potential to”. Forward-looking statements contained in this press release are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Among those factors which could cause actual results to differ materially are the following: market conditions and other risk factors listed from time to time in our reports filed with Canadian securities regulators on SEDAR+ at www.sedarplus.ca. The forward-looking statements included in this press release include, without limitation, statements regarding the Offering, the closing of the Offering, the anticipated closing date of the Offering, the intended use of proceeds from the Offering and the receipt of any necessary approvals, including approval of the Toronto Stock Exchange. The forward-looking statements included in this press release are made as of the date of this press release and Forsys Metals Corp. disclaim any intention or obligation to update or revise any forward-looing statements, whether as a result of new legislation, future events or otherwise, expect as expressly required by applicable securities legislation.

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND

TNX-2900 granted Orphan Drug and Rare Pediatric Disease Designations by the FDA, providing the potential for a Priority Review Voucher upon approval

Magnesium-potentiated intranasal oxytocin formulation designed to reduce dose-related inconsistencies in receptor activity

CHATHAM, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated commercial-stage biotechnology company with innovative marketed products and a pipeline of development candidates, today announced plans to progress its TNX-2900 program for the treatment of Prader-Willi syndrome (PWS) into a Phase 2 clinical trial. TNX-2900 is a proprietary magnesium-potentiated intranasal oxytocin formulation designed to improve receptor binding and decrease dose-related inconsistencies in receptor activity. The program has received both Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA), which would make Tonix eligible for a transferable Priority Review Voucher, upon approval. The FDA has cleared the Investigational New Drug (IND) application for TNX-2900 to progress into Phase 2 development.

“We are pleased to advance TNX-2900 into a Phase 2 trial for PWS, a condition with unmet needs for new medicines with activity and tolerability,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Families caring for children with PWS face significant challenges and burdens. Among them is hyperphagia which drives persistent food-seeking behaviors that require constant supervision and often result in obesity and serious medical complications. With an average life expectancy of less than 30 years, treatment of PWS remains an urgent and unmet need. By addressing limitations of traditional oxytocin delivery, we believe TNX-2900 has the potential to become an FDA-approved therapy targeting the oxytocin receptor in PWS and provide meaningful benefit for patients and families living with this rare disorder.”

Tonix plans to conduct a Phase 2 randomized, double-blind, placebo-controlled, parallel-design study to evaluate the safety, tolerability, and efficacy of TNX-2900 in male and female participants with PWS, ages 8 to 17.5 years. Eligible participants will be randomized to receive 12-weeks of treatment with TNX-2900 at one of three dose levels, or placebo, in a 1:1:1:1 ratio. The primary efficacy endpoint will be the change from baseline in the validated Hyperphagia Questionnaire for Clinical Trials (HQ-CT), a widely used measure of hyperphagia severity in PWS. Secondary objectives will include assessments of behavior, caregiver burden, and quality of life measures, as well as safety and tolerability outcomes.

Prader-Willi syndrome (PWS) is a rare genetic disorder and the leading cause of life-threatening childhood obesity, affecting about 1 in 10,000 to 1 in 30,000 births. Infants often present with poor muscle tone and feeding difficulties, while children and adolescents develop hyperphagia, behavioral challenges, and severe obesity and metabolic disease. Current interventions are difficult to sustain and often inadequate.

Research suggests PWS is associated with a functional deficiency of oxytocin, a neuropeptide that regulates satiety and feeding behaviors through the oxytocin receptor. Oxytocin treatment addresses several key features of PWS expressed in the MAGEL2 (MAGE-like 2) knock-out mouse.1 Intranasal oxytocin therapy has shown benefits in infants with PWS.2   Carbetocin has a different spectrum of activity on oxytocin and vasopressin receptors than oxytocin and carbetocin has not been tested to our knowledge in the MAGEL2 knock-out mouse.3 Oxytocin has dose-related inconsistencies in receptor activity that have been described as “high-dose suppression” or an “inverted “U” dose response.4 TNX-2900 is formulated with magnesium to further enhance oxytocin receptor binding and signaling, with the goal of providing more consistent and selective receptor activation while minimizing off-target vasopressin effects. In vitro and in vivo in animals Mg++- containing formulations reduce these inconsistencies.4

About Prader-Willi Syndrome (PWS)

PWS is recognized as the most common genetic cause of life-threatening childhood obesity and affects males and females with equal frequency and all races and ethnicities. PWS results from the absence of expression of a group of genes, specifically related to the MAGE (melanoma antigen) gene family on the Prader–Willi critical region (15q11–q13) on the paternally acquired chromosome. The hallmarks of PWS are lack of suckling in newborns and, in children and adolescents, severe hyperphagia – an overriding physiological drive to eat, leading to severe obesity and other complications associated with significant mortality. A systematic review of the morbidity and mortality as a consequence of hyperphagia in PWS found that the average age of death in PWS was 22.1 years.5 Given the serious or life-threatening manifestations of these conditions, there is a critical need for effective treatments to decrease morbidity and mortality, improve quality of life, and increase life expectancy in people with PWS. Oxytocin has potent effects in correcting behavioral characteristics of the MAGEL2 knock-out mouse model for PWS and autism. 1,6,7 Six clinical trials have investigated intranasal oxytocin as a treatment in pediatric patients with PWS. Four clinical studies showed evidence for improvement in PWS-related behaviors/symptoms/2,810 Three of these clinical studies reported evidence for improvement in hyperphagia8-10 and one showed an improvement in sucking in infants.2

Schaller F, et al. Hum Mol Genet. 2010. 19:4895-4905.Tauber M, et al. Pediatrics. 2017. 139(2):e20162976.Meyerowitz JG, et al. Nat Struct Mol Biol. 2022 29(3):274-281.Bharadwaj VN, et al. Pharmaceutics. 2022 14(5):1105.Bellis SA, et al. Eur J Med Genet. 2022. 65(1):104379.Bertoni A, et al. Mol Psychiatry. 2021. 26(12):7582-7595.Meziane H, et al. Biol Psychiatry. 2015. 78: 85-94.Kuppens RJ, et al. Clin Endocrinol. 2016. 85:979-987.Miller JL et al. Am J Med Genet A. 2017. 173:1243-1250.Damen L, et al. Clin Endocrinol. 2020. 94:774-785. About TNX-2900 and Tonix’s Potentiated Oxytocin Platform

TNX-2900 is based on Tonix’s patented intranasal Mg2+-potentiated oxytocin formulation intended for use by children and adolescents. This formulation is believed to enhance the potency of oxytocin as well as increase specificity for oxytocin receptors relative to vasopressin receptors, potentially reducing unwanted side effects from activating vasopressin receptors. In collaboration with academic investigators, Tonix is also testing a different intranasal formulation, designated TNX-1900 for adolescent obesity, binge eating disorder, bone health in autism, and social anxiety disorder. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. Oxytocin is believed to be more than 600 million years old and is present in vertebrates including mammals, birds, reptiles, amphibians, and fish. It was initially approved by the U.S. Food and Drug Administration as Pitocin®, an intravenous infusion or intramuscular injection drug, for use in pregnant women to induce labor and control postpartum bleeding or hemorrhage. An intranasal formulation of oxytocin is marketed in some European countries to assist in breast milk production as Syntocinon® (oxytocin nasal 40 international units/ml).

Tonix Pharmaceuticals Holding Corp.*

Tonix Pharmaceuticals is a commercial-stage, fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix recently received FDA approval for TonmyaTM, a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. This marks the first approval for a new prescription medicine for fibromyalgia in more than 15 years. Tonix also markets two treatments for acute migraine in adults. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, immunology, immuno-oncology and infectious diseases. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize Tonmya and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris 
Tonix Pharmaceuticals 
[email protected] 
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
[email protected] 

Media Contact 
Ray Jordan 
Putnam Insights 
[email protected] 
 

INDICATION

TONMYA is indicated for the treatment of fibromyalgia in adults.

CONTRAINDICATIONS

TONMYA is contraindicated:

In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected.

With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.

During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.

In patients with hyperthyroidism.

WARNINGS AND PRECAUTIONS

Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.

Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.

Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.

Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.

CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities.

Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.

DRUG INTERACTIONS

MAO inhibitors: Life-threatening interactions may occur.

Other serotonergic drugs: Serotonin syndrome has been reported.

CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.

Tramadol: Seizure risk may be enhanced.

Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).

Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of TONMYA have not been established.

Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.

Please see additional safety information in the full Prescribing Information.

To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

September 29, 2025 07:00 ET

 | Source:

Vor Biopharma

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois.

Late-Breaking Presentation Details

Abstract Title: Efficacy and Safety of Telitacicept in Patients with Sjögren's Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study

Session: Late-Breaking Posters

Date & Time: Tuesday, October 28th, 10:30 AM – 12:30 PM CT

In early September, RemeGen announced the acceptance by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China of its Biologics License Application (BLA) for primary Sjögren’s disease, which will become telitacicept’s fourth approved indication in China.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

About Telitacicept
Telitacicept is a novel, investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. In a Phase 3 clinical trial in generalized myasthenia gravis in China, telitacicept demonstrated a placebo adjusted 4.83-point improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living scale) at 24 weeks, the primary endpoint of the trial.

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, South America, and Asia-Pacific to support potential approval in the United States, Europe, and Japan.

About Sjögren’s Disease (formerly known as Sjögren’s Syndrome)
Sjögren’s disease is a chronic autoimmune condition in which overactive B cells drive inflammation, damaging moisture-producing glands and, in many cases, other organs. Hallmark symptoms include dry eyes and dry mouth, alongside fatigue, pain, and systemic complications affecting the skin, lungs, kidneys, and nervous system. About one-third of patients develop significant extraglandular involvement, and the disease carries an elevated lymphoma risk, often leading to substantial impairment in daily life.

One of the most common rheumatic autoimmune diseases, Sjögren’s remains underdiagnosed, with roughly half of cases unrecognized and women comprising the vast majority of patients. Despite its prevalence and burden, no systemic disease-modifying therapies exist; current care focuses on symptom management with incomplete relief.

Media & Investor Contacts:
Carl Mauch
[email protected]

Sarah Spencer
[email protected]

MONTREAL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce that it has confirmed a historical spodumene pegmatite and discovered a second one at its Paamiut project in Greenland. Brunswick Exploration now has two projects with confirmed lithium showings in Greenland and is the only company actively looking for lithium in Greenland.

Mr. Killian Charles, President and CEO of BRW, commented: “Following the expansive new discoveries at our Nuuk Project, this new Paamiut discovery is a great complement to our unique Greenland portfolio. These additional lithium-bearing pegmatites highlight the team's ability to identify and make new grassroots discoveries. We are evaluating next steps at Paamiut and have already begun planning for a maiden drill program at Nuuk. All of BRW’s Greenland discoveries are in proximity to fjord infrastructure, and with ties to Europe, we are very excited to continue our efforts in Greenland. Combined with an active drill program at its Anatacau Main project and a forthcoming resource estimate at the Mirage project, both in Quebec, BRW is among the most aggressive lithium exploration globally.”

Paamiut Confirmation and Discovery

BRW has confirmed a historical spodumene-bearing pegmatite and discovered a second dyke at the Company's Paamiut Project. The discoveries are approximately 26 kilometers from Paamiut, a coastal community located about 260 kilometers south of Nuuk in Western Greenland. The dykes are hosted within a large shear zone and are found within a roughly 10-kilometer by 2-kilometer greenstone belt (see news release dated February 18th, 2025).

The spodumene pegmatites are roughly 3-6 meters wide, 40-60 meters long, and are spaced approximately 10 meters apart from one another. Lithium mineralization is primarily spodumene, which varies from 5-30%, containing pale green crystals ranging from 1 to 10 centimeters in size. The Company believes that there is potential to host additional spodumene pegmatites within the greenstone belt. Spodumene mineralization was confirmed by both pXRF and LIBS units. Grab samples were sent for analysis to ALS in Dublin, Ireland, and thin section samples will be prepared for further mineralogical studies.

Greenland Portfolio Update

During the summer campaign, the team completed first-pass prospecting on all western Greenland Licences while advancing both Nuuk and Paamiut. Due to continued exploration successes at Nuuk and Paamiut, additional time was not available to conduct first-pass prospecting at the Hinksland License located in Eastern Greenland. However, the team is already planning the next opportune time to evaluate that Licence. Additional spodumene discoveries were not identified outside of the Nuuk and Paamiut areas at this time.

Corporate Update

BRW also wishes to announce that Mr. Mathieu Savard has resigned as a director of the Company in order to focus all of his time and attention on his role as Chief Executive Officer and President of Vior Inc. On behalf of the board and shareholders, Brunswick Exploration would like to thank Mathieu for his contributions to the Company over the years.

Figure 1: Paamiut pXRF Data

Figure 2: Paamiut Spodumene Pegmatite – Looking West

Figure 3: Spodumene Crystals - Paamiut

Qualified Person

The scientific and technical information related to this press release has been reviewed and approved by Mr. Charles Kodors, Manager, International Projects. He is a Professional Geologist registered in New Brunswick, Newfoundland and Quebec.

About Brunswick Exploration

Brunswick Exploration is a Montreal-based mineral exploration company listed on the TSX-V under symbol BRW. The Company is focused on grassroots exploration for lithium, a critical metal necessary to global decarbonization and energy transition. The company is rapidly advancing one of the extensive grassroots lithium property portfolios in Canada and Greenland including the Mirage Project.

Investor Relations/information

Mr. Killian Charles, President and CEO ([email protected])

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Cautionary Statement on Forward-Looking Information

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation’s public documents filed on SEDAR at www.sedar.com. Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Photos accompanying this announcement are available at: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/7e80816e-c400-4d36-af7d-1e9d394fdc48

https://www.globenewswire.com/NewsRoom/AttachmentNg/da90ba91-e674-4c27-82ed-063698551458

https://www.globenewswire.com/NewsRoom/AttachmentNg/9fe58eaf-e58c-464d-bc56-ed7a18d73859

Wall Street logged a downbeat performance last week.The S&P 500 declined 0.3%, the Dow edged lower by 0.2%, and the Nasdaq slipped 0.7%, marking the first weekly loss in four weeks for the Nasdaq and the S&P 500, as quoted on CNBC.

Inflation Data in FocusAugust’s personal consumption expenditures (PCE) price index, the Federal Reserve’s preferred measure of inflation, came in as expected. Core PCE, barring food and energy, rose at an annual rate of 2.9%, while the all-items index recorded a 2.7% increase year over year and a 0.3% monthly gain. These readings, though still above the Fed’s 2% target, reaffirmed expectations for two quarter-point interest rate cuts by the year-end, per the CNBC article.

Consumer Sentiment Consumer sentiment for September, reported by the University of Michigan, was only slightly weaker than expected and held steady among wealthier households with larger stock holdings. The survey’s index of consumer sentiment recorded a reading of 55.1, just slightly below the Dow Jones consensus forecast of 55.4 (as quoted on CNBC).

The reading marked a 5.3% decline month over month and a 21.6% slump from the same period a year ago.Inflation expectations held stable, with the one-year outlook at 4.7% and the five-year at 3.7%, as quoted on the abovementioned CNBC article.

Upbeat GDP Growth DataThanks to stronger consumer spending, the U.S. economy grew at an unexpectedly robust 3.8% pace in Q2 of 2025, marking an upward revision of second-quarter growth released by the government.

The Commerce Department said that gross domestic product (GDP) bounced back in the spring after a 0.6% decline in the first quarter, which had been hit hard by trade tensions. The new estimate is higher than the previously reported 3.3% growth (per AP news, as quoted on Yahoo Finance).

Fed Rate Cut to Address Weakening Labor Market The Fed enacted its first rate cut of 2025 in September and also hinted at further cuts this year.At the time of writing, there are 87.7% chances of a 25-bp rate cut in the October meeting, per the CME FedWatch Tool. 

Moderate Comeback of Tariff TensionsIn a trio of posts on Truth Social on Sept. 25, 2025, President Trump announced that the U.S. will roll out a host of tariffs starting Oct. 1. The measures will cover imported kitchen cabinets, bathroom vanities, pharmaceutical products, and heavy trucks. Tariffs will range from 30% to 100%, though exemptions will apply to drugmakers currently building manufacturing plants in the United States, as quoted on Yahoo Finance.

Against this backdrop, below we highlight a few winning leveraged exchange-traded funds (ETFs) of the last week.

Leveraged IntelGraniteShares 2x Long INTC Daily ETF (INTW - Free Report) – Up 41.9%

Intel (INTC - Free Report) stock jumped 19.7% last week. Intel has been in the news lately as it secured hefty investments from NVIDIA to facilitate its turnaround. Intel is reportedly planning to tie up with Apple for investments, too, as quoted on Bloomberg. Intel also announced in late August thatthe United States government will make an $8.9 billion investment in Intel common stock.

Leveraged Webull GraniteShares 2x Long BULL Daily ETF (BULX - Free Report) – Up 28.8%

Leverage Shares 2X Long BULL Daily ETF (BULG - Free Report) – Up 28.8%

Shares of Webull (BULL - Free Report) – the operator of a digital investment platform – gained about 14% last week.  In early September, Webull Corporation announced its expansion into the European market by launching brokerage services in the Netherlands through its newly authorized Amsterdam-based subsidiary, Webull Securities (Europe) B.V.

Leveraged LucidGraniteShares 2x Long LCID Daily ETF (LCDL - Free Report) – Up 28.7%

Lucid Group (LCID) stock rose 13.7% last week. The company is targeting production of 18,000–20,000 EVs in 2025, more than double last year’s output. The company is also focusing on battery recycling through RecycLiCo.

Leveraged Marvell Technology GraniteShares 2x Long MRVL Daily ETF (MVLL - Free Report) – Up 24.4%

Marvell Technology Inc. (MRVL - Free Report) stock jumped 13.2% last week. The company’s chief executive offered analysts an upbeat outlook of the company's prospects. At an investor conference held last week, Chief Executive Matt Murphy said the company's custom chip business should see no revenue gap next year, despite concerns related to the status of its business with Amazon's (AMZN) AWS unit, as quoted on investors.com.

Garmin extends its winning streak, now recognized with 72 prestigious NMEA honors  for excellence across marine product, service and support categories

, /PRNewswire/ -- Garmin (NYSE: GRMN), the world's most innovative and recognized marine electronics manufacturer, has been named Manufacturer of the Year in the large manufacturer category for the 11th consecutive year by members of the National Marine Electronics Association (NMEA®) at its annual conference and awards banquet held Sept. 25 in West Palm Beach, Fla. The coveted Manufacturer of the Year title is awarded to the most recognized company in the marine electronics industry for excellence in product service and support in the field.

Garmin has been named Manufacturer of the Year for the 11th consecutive year by members of the National Marine Electronics Association (NMEA®) at its annual conference and awards banquet held Sept. 25 in West Palm Beach, Fla., and received eight Product of Excellence awards across various categories.

Garmin was also awarded eight Product of Excellence awards in the multi-function display (MFD), fishfinder, autopilot, multimedia entertainment, automatic identification system (AIS), marine safety device, satellite communication antenna and marine specialty product categories. These awards are voted on by NMEA dealers who specialize in installing marine electronics, qualified NMEA technicians and other marine electronics manufacturers.

"It's a tremendous honor to be recognized by the NMEA as Manufacturer of the Year for 11 years running and to extend our product of excellence awards across so many categories. This recognition reflects the dedication of our entire team to delivering innovative marine technology, exceptional service and unwavering support to our customers. Garmin's momentum in the marine industry shows no signs of slowing and we look forward to continuing to work alongside the NMEA to shape the future of marine technology." –Dave Dunn, Garmin Senior Director Marine & RV Sales

This year's NMEA Product of Excellence honors for Garmin include:

MFD: GPSMAP® 9227
At 27 inches, this is the industry's largest integrated 4K resolution touchscreen chartplotter. Garmin has won the MFD category for 11 consecutive years.
Fishfinder: GSD™ 28
Premium sonar module powered by RapidReturn™ sonar with next-gen xCHIRP technology for Garmin's clearest and most detailed fish arch returns with a 10,000-foot range.
Autopilot: Reactor™ 40 Hydraulic Autopilot with SmartPump v2
Recreational autopilot system with AHRS technology. This is Garmin's 13th consecutive honor in the autopilot category.
Multimedia Entertainment: Fusion® Apollo™ RA770 Marine Stereo
Premium audio source unit with built-in Wi-Fi®. Garmin has earned top honors in the multimedia entertainment category for a decade.
AIS: Cortex® M1 Hub
Communication hub with smartAIS® transponder and remote vessel monitoring. For four years running, Garmin has won the AIS category.
Marine Safety Device: inReach® Mini 2 Marine Bundle
Lightweight and compact SOS satellite communicator with navigation and two-way text messaging1, bundled with a boat-friendly mount.
Satellite Communication Antenna: inReach Messenger Plus
SOS satellite communicator with two-way text, photo and voice messaging1. This is Garmin's second consecutive win in the satellite communication antenna category.
Marine Specialty Product: quatix® 8 Marine GPS Smartwatch
Nautical smartwatch with AMOLED display, chartplotter controls and built-in flashlight.
"These awards showcase the very best in marine electronics technology. Every year, our members and certified installers select products that they trust and rely on to deliver performance, safety, and innovation on the water." –Mark Reedenauer, NMEA President and Executive Director

Engineered on the inside for life on the outside, Garmin products have revolutionized life for anglers, sailors, mariners and boat enthusiasts everywhere. Committed to developing the most innovative, highest quality, and easiest to use marine electronics the industry has ever known, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. For more information, visit Garmin's virtual Newsroom, email our press team, connect with @garminmarine on social media, or follow our blog.

1 Active satellite subscription required. Some jurisdictions regulate or prohibit the use of satellite communication devices. It is your responsibility to know and follow applicable laws in jurisdictions where the device is intended to be used. 

About Garmin International, Inc. Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin, GPSMAP, Fusion, Cortex, smartAIS, inReach and quatix are registered trademarks, and GSD, RapidReturn, Reactor and Apollo are trademarks of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.

Notice on Forward-Looking Statements:
This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 28, 2024, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983), and the Quarterly Report on Form 10-Q for the quarter ended June 28, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 001-41118). Copies of such Form 10-K and Form 10-Q are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

MEDIA CONTACT:
Carly Hysell
913-397-8200
[email protected] 

SOURCE Garmin International, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Metavesco, Inc. (OTC: MVCO), a pioneering diversified holding company and the developer of OTCfi, today announced plans to launch OTCfi Nexus, a groundbreaking initiative to establish a credit infrastructure for OTC companies.

OTCfi Nexus is being developed as the go-to funding source of the OTC.

OTCfi Nexus is being developed as the go-to funding hub of the OTC, providing a transparent platform for loans and credit lines. Through Nexus, OTC companies will be able to connect their wallets, verify OTCfi holdings, and apply for capital. A real-time, publicly visible dashboard will track repayment progress and borrower performance, bringing new levels of transparency and accountability to the OTC ecosystem.

"With OTCfi Nexus, we're taking OTCfi from token to infrastructure," said Ryan Schadel, CEO of Metavesco. "This launch is about proving the concept, giving OTC companies transparent access to capital while creating real utility and locked supply for OTCfi. We expect Nexus to be fully operational before year-end."

OTCfi: Built to Rally, Built for the Future

Metavesco launched OTCfi as a community token for the OTC with a simple purpose: to unite issuers, traders, and investors around a shared asset that adds transparency, energy, and credibility to the space. The token has been adopted by multiple OTC companies for treasury purposes and has grown into a platform for contests, staking, and community engagement.

The launch of Nexus represents the next step in this vision; evolving OTCfi from a symbolic treasury asset into a functional layer of credit and financial utility for the entire OTC ecosystem.

Key features planned for the OTCfi Nexus launch include:

Loan & Credit Portal: OTC companies connect wallets, verify OTCfi holdings, and request USDC-based loans, up to 300% LTV.
Real-Time Dashboard: Transparent tracking of repayment status, empowering accountability and trust. Over time, this transparency will effectively create a "social credit score" within the trading community, where well-performing companies build reputational capital and underperformers are flagged by their record.
Collateralized Lending: OTCfi used as collateral, reducing circulating supply and creating direct financial utility.
The Future Vision

Beyond its beta launch, Metavesco envisions OTCfi Nexus growing into a fully regulated platform where OTC companies with OTCfi on their balance sheet can raise capital directly from the investing public. This long-term roadmap aims to provide small OTC issuers with an alternative to toxic funding arrangements that have historically weighed down the market.

Achieving this vision will require significant regulatory development, and Metavesco is committed to pursuing this work in a manner that is fully SEC-compliant. By combining transparency, compliance, and community alignment, OTCfi Nexus has the potential to reshape how OTC companies access growth capital and make a positive impact on the OTC market structure.

Metavesco is actively working to onboard funding partners who will help scale loan capacity and broaden the reach of OTCfi Nexus. The Company expects to announce its first funding partner imminently.

This announcement was made live on the pump.fun platform. All previous OTCfi livestreams on the pump.fun platform can be viewed here: pump.fun/coin/66MH83n3jRqZMni87niTyKRoGbh9HxBkTm73sTRKpump.
To learn more about OTCfi, visit www.otcfi.io.

About Metavesco, Inc.

Metavesco is a diversified holding company focused on acquiring and managing assets across multiple sectors, including consumer packaged goods and staffing services. The company is dedicated to long-term growth through organic expansion, strategic acquisitions and innovative market solutions.

Safe Harbor Statement

This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.

SOURCE Metavesco, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Report shows completing manual data reconciliation, cleaning, and review takes each data manager more than 12 hours per week, per study

, /PRNewswire/ -- SCDM 2025 — Two-thirds of data managers and clinical research associates (CRAs) report that inefficiencies in manual data reconciliation, cleaning, and review will put clinical data quality at future risk. The Veeva Clinical Data Industry Research shows the main drivers adding time and effort in executing clinical trials are too many manual steps or data re-entry (68%), inefficient workflows (58%), and using multiple disconnected systems (59%). The findings highlight a need to automate the most inefficient data management processes for improved speed and productivity.

Each round of manual data review, cleaning, and reconciliation takes a data manager more than 12 hours per week, per study to complete. This is because nearly all respondents (97%) perform reconciliation outside of clinical systems or use a mix of systems to complete the process. The disconnected approaches increase the burden on clinical teams and the risk of poor data quality.

Key insights from the research on the state of clinical data management include:

Automation is the number one priority for data managers. When asked how the data manager role will evolve over the next two years, 71% of respondents say they expect to be using more automation for data cleaning. Automated processes across technologies can shift effort from spreadsheets to strategic initiatives, like risk-based data management.

CRAs want better documentation and tracking. The lack of connectivity across clinical systems requires CRAs to conduct manual validation of monitoring visits. Nearly half (44%) say improving documentation and tracking is their top priority.

Complexity, resources, and resistance to change are barriers. The main challenges to efficiency include protocol complexity (58%), budget and resource constraints (57%), and resistance to change (48%). This shows an opportunity for clinical leaders to continue driving change for data managers and CRAs to work in new, more effective ways.

Connected systems viewed as key to productivity. Most respondents (81%) believe connecting clinical systems would streamline study execution. The report shows 75% of data managers say their teams are in the process of modernizing compared to 57% of CRAs, yet many feel SOPs do not optimize use of available tools or align with real-world workflows, highlighting a gap that can prevent progress.

"The risk of poor data quality spans far beyond a monitoring visit or listing review, potentially impacting regulatory submission success. The research shows that the people executing studies need change and are asking for simpler processes and automation for more efficient clinical trials," said Manny Vazquez, senior director, Veeva Clinical Data strategy.

The Veeva Clinical Data Industry Research surveyed more than 85 data managers and CRAs across sponsors and clinical research organizations (CROs) who use various technologies and tools to execute clinical trials. The research examines productivity in Phase III trials, identifies root causes, and offers insights for advancement. To learn more, read the full report.

About Veeva Systems
Veeva (NYSE: VEEV) delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Deivis Mercado
Veeva Systems
925-226-8821
[email protected]

SOURCE Veeva Systems

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the treatment of first-line patients with advanced melanoma Company implementing a restructuring, reducing its workforce by approximately 50 percent NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today provided an update on the regulatory pathway for Cylembio® (imsapepimut and etimupepimut, adjuvanted) following a pre-BLA meeting with the U.S. Food and Drug Administration (FDA).

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

HomeIndustriesThe Ratings GameThe Ratings GamePublished: Sept. 29, 2025 at 5:36 a.m. ET

Novo Nordisk was downgraded to underweight by Morgan Stanley. Photo: mads claus rasmussen/Agence France-Presse/Getty ImagesMorgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster weight-loss drug also will work against Alzheimer’s is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.

Morgan Stanley cut Novo Nordisk’s NVO DK:NOVO.B rating to underweight from equal weight and cut the price target on its U.S.-listed stock to $47 from $59.

About the Author

Steven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was Washington bureau chief, directing MarketWatch's economic, political and regulatory coverage. Follow Steve on Twitter: @MKTWgoldstein.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Maranello (Italy), September 29, 2025 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 360 million share buyback program announced on July 31, 2025, as the eighth tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in line with the disclosure made during the 2022 Capital Markets Day (the “Eighth Tranche”), the additional common shares - reported in aggregate form, on a daily basis - on the Euronext Milan (EXM) and on the New York Stock Exchange (NYSE) as follows:

 EXMNYSETotalTradingNumber of common shares purchasedAverage price per shareConsideration excluding feesNumber of common shares purchasedAverage price per shareConsideration excluding feesConsideration excluding feesNumber of common shares purchasedAverage price per shareConsideration excluding feesDateexcluding fees excluding fees  excluding fees (d/m/y)(€)(€)($)($)(€)*(€)*(€)*        22/09/202510,200403.70594,117,800.188,333478.94443,991,043.693,387,695.1718,533404.98017,505,495.3523/09/20256,000409.39942,456,396.40----6,000409.39942,456,396.4024/09/20259,364409.76953,837,081.60----9,364409.76953,837,081.6025/09/202513,100406.41125,323,986.72----13,100406.41125,323,986.7226/09/20259,300405.82843,774,204.12----9,300405.82843,774,204.12 47,964406.752319,509,469.028,333478.94443,991,043.693,387,695.1756,297406.720922,897,164.19Total  (*) translated at the European Central Bank EUR/USD exchange reference rate as of the date of each purchase

        Since the announcement of such Eighth Tranche till September 26, 2025, the total invested consideration has been:

Euro 99,130,160.87 for No. 242,324 common shares purchased on the EXMUSD 33,447,541.72 (Euro 28,547,995.07*) for No. 69,609 common shares purchased on the NYSE. As of September 26, 2025, the Company held in treasury No. 16,017,908 common shares, net of shares assigned under the Company’s equity incentive plan, corresponding to 8.26% of the total issued common shares. Including the special voting shares, the Company held in treasury 8.82% of the total issued share capital.
Since the start of the multi-year share buyback program of approximately Euro 2 billion announced during the 2022 Capital Markets Day, on July 1, 2022, until September 26, 2025, the Company has purchased a total of 5,322,953 own common shares on EXM and NYSE, including transactions for Sell to Cover, for a total consideration of Euro 1,770,247,853.29.

A comprehensive overview of the transactions carried out under the buyback program, as well as the details of the above transactions, are available on Ferrari’s corporate website under the Buyback Programs section (https://www.ferrari.com/en-EN/corporate/buyback-programs).

For further information:
Media Relations
tel.: +39 0536 949337
Email: [email protected]

FNV BB PR 29 September 2025 ENG

Touchstone Exploration Inc (AIM:TXP, TSX:TXP, OTC:PBEGF) shares trade lower, down 9%, after it ended drilling operations in the Cascadura-4 development well earlier than planned.

The company, in a statement, flagged problems in the well (including a drill bit becoming and remaining stuck), which meant a full analysis of the reservoir could not be conducted.

Nevertheless, the company told investors that the available results are consistent with its geological model.

"While Cas-4ST2X presented challenges due to re-entering a previous wellbore, the systems implemented on the Cas-5 well have proven effective," said chief executive Paul Baay.

Touchstone said it would now start completion work for the Cascadura-5 well, and both the new wells are set to be tied into the existing natural gas facility.

In London, Touchstone shares were down 9% changing hands at 12.60p.

September 29, 2025 06:00 ET

 | Source:

USA Rare Earth, Inc.

Previously Served as President and CEO of Siemens USA

Proven Leader with Decades of Experience Managing and Growing Complex, Technology-Driven Organizations in the Critical Infrastructure and National Defense Industries

STILLWATER, Okla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company) today announced that its Board of Directors has appointed Barbara Humpton as the Company’s Chief Executive Officer to succeed Josh Ballard, effective October 1, 2025. Humpton will also serve on USAR’s Board of Directors.

“Today marks a pivotal moment for USAR as Barbara becomes our next CEO,” said Michael Blitzer, Chairman of USA Rare Earth. “Barbara is a transformational and visionary leader who joins USAR at a time of incredible opportunity and growth. In her 14 years at Siemens, most recently as CEO of Siemens USA, Barbara developed organic initiatives and integrated numerous large acquisitions to grow it into one of North America’s largest and most recognizable industrial companies with more than $20 billion of revenues.”

“Barbara is an established global leader in the areas that matter to us, including critical infrastructure, technology, and strategic national defense, and brings years of experience engaging with government entities,” Blitzer noted. “I would also like to offer thanks to Josh Ballard for his contributions to USA Rare Earth. I look forward to working with Barbara and the rest of the talented leadership team to deliver on our vision of becoming the leading supplier of critical rare earth minerals and magnets.”

“Throughout my career, I have been motivated by being part of missions that matter, and there is nothing more critical to national and global security than securing a domestic supply chain for rare earth minerals and magnets,” said Humpton. “USA Rare Earth is uniquely positioned to be the leader in this industry with its mine-to-magnet supply chain strategy, anchored now by mining rights to a domestic deposit rich in valuable heavy rare earth elements, unique metal making know how and technology, and one of the largest magnet production facilities under construction outside of China. I am incredibly excited about joining USAR and am committed to devoting my time, talent and efforts as it executes on its bold and transformative vision to build an American champion for the benefit of America and our allies.”

Humpton most recently served as President and CEO of Siemens USA. Prior to being named President and CEO of Siemens USA in 2018, Humpton served as President and CEO of Siemens Government Technologies, responsible for implementing Siemens products and services for federal government agencies and departments. Prior to joining Siemens in 2011, Humpton served as a vice president at Booz Allen Hamilton and was a Vice President and Director at Lockheed Martin Corporation.

Humpton serves on the Board of Directors of the Federal Reserve Bank of Richmond. She is also Chair of the Board of the Center for Strategic and Budgetary Assessments (CSBA). She has served on the boards of the National Association of Manufacturers (NAM), Chief Executives for Corporate Purpose (CECP), and the Economic Club of Washington, D.C. Humpton also served on the Board of Directors of Triumph Group until its acquisition in 2025 by Warburg Pincus and Berkshire Partners. 

Humpton succeeds Joshua Ballard, who has agreed to remain with the Company in a consulting capacity through October 31, 2025.

About USA Rare Earth
USA Rare Earth, Inc. (Nasdaq: USAR) is developing a rare earth sintered neo magnet (“NdFeB” or “neo”) manufacturing plant in Stillwater, Oklahoma, and intends to establish domestic rare earth and critical minerals supply, extraction, and processing capabilities to both supply its magnet manufacturing plant and market surplus materials to third parties. Rare earth magnets are critical to various business sectors and industries, including the defense, automotive, aviation, industrial, AI Robotics, medical, and consumer electronics industries, among others. USAR is planning to take a broad approach to the industries it serves with the intention of providing high quality neo magnets to a variety of industries and customers. USAR’s focus on developing domestic rare earth production aligns with national priorities, offering the potential of a sustainable and secure domestic supply of materials critical to key industries.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws. Words such as “future,” “will,” “executes,” “vision,” “commitment,” “expect” and similar expressions identify forward-looking statements, which include but are not limited to statements related to the future vision and plans for the Company. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to the Company’s ability to successfully develop its magnet production facility and the timing of expected production milestones, as well as the factors identified in the risk factors of the Company’s periodic filings with the SEC, including the Company’s Form 10-K that the Company filed with the SEC on March 31, 2025 and the Company’s latest Quarterly Reports on Form 10-Q filed with the SEC. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements speak only as of their date, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances occurring after their date or to reflect the occurrence of unanticipated events.

Investor Contacts:
Rob Steele
CFO
[email protected]

Lionel McBee
VP, Investor Relations
[email protected]

Scottsdale, Arizona, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outdoor Holding Company (NASDAQ: POWW/POWWP) (“Outdoors Online,” “we,” “us.” “our” or the “Company”), the owner of GunBroker.com, the largest online marketplace for firearms, hunting and related products, today announced that the United States District Court for the Northern District of Georgia has granted its motion for summary judgment in a contributory trademark infringement action brought by Microtech Knives, Inc. The Court concluded that GunBroker.com is an online marketplace, and as such, had fully satisfied its obligations to protect the intellectual property of third parties once potential infringing actions were brought to its attention. Furthermore, the Court validated GunBroker’s effective policies and procedures to combat infringement and counterfeiting issues when put on notice.

Chairman and Chief Executive Officer Steve Urvan said, “We are very pleased to have the Court confirm our status as an online marketplace, just like eBay or Etsy, with the rights and obligations associated with being an online marketplace. The court recognized the effectiveness of our policies and procedures and our continued commitment to protect the intellectual property of third parties. This decision will put an end to this matter and will allow us to avoid unnecessary legal costs and associated distractions. We look forward to continuing to improve and grow our Company as a pure-play online marketplace for firearms and outdoor enthusiasts.”

The Court decision arose from litigation initiated in March 2023 by Microtech Knives, Inc. against GunBroker.com for contributory infringement of its trademark rights. The litigation was part of a larger action brought against a GunBroker seller for allegedly selling products that infringed Microtech trademarks on the GunBroker.com site in 2023.

About Outdoor Holding Company

With its corporate offices headquartered in Scottsdale, Arizona, Outdoor Holding Company is a publicly traded corporation that owns and operates subsidiaries serving outdoor enthusiasts, including GunBroker.com

About GunBroker

GunBroker.com is the largest online marketplace dedicated to firearms, hunting, shooting and related products. Aside from merchandise bearing its logo, GunBroker currently sells none of the items listed on its website. Third-party sellers list items on the site and Federal and state laws govern the sale of firearms and other restricted items. Ownership policies and regulations are followed using licensed firearms dealers as transfer agents. Launched in 1999, GunBroker is an informative, secure and safe way to buy and sell firearms, ammunition, air guns, archery equipment, knives and swords, firearms accessories and hunting/shooting gear online. GunBroker promotes responsible ownership of firearms. For more information, please visit: www.gunbroker.com.

Forward-Looking Statements

This document contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies, goals and objectives of management for future operations; any statements concerning proposed new products and services or developments thereof; any statements regarding future economic conditions or performance; any statements or belief; and any statements of assumptions underlying any of the foregoing.

Forward looking statements may include the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words, or the negative thereof. These forward-looking statements present our estimates and assumptions only as of the date of this report. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the dates they are made. You should, however, consult further disclosures and risk factors we include in Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports filed on Form 8-K.

Investor Contact:       Michael Bacal
                                  [email protected]
                                  917-886-9071

Heineken N.V. reports the progress of transactions under its current share buyback programme

Amsterdam, 29 September 2025 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025.

From 19 September 2025 up to and including 26 September 2025 a total of 184,735 shares were repurchased on exchange at an average price of € 66.02. During the same period, 185,396 shares were repurchased from Heineken Holding N.V..  

Up to and including 26 September 2025, a total of 6,104,457 shares were repurchased under the share buyback programme for a total consideration of € 443,371,257 (including shares repurchased from Heineken Holding N.V.).

Heineken N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.theheinekencompany.com/investors/share-information/share-buyback-programme

Enquiries

Media InvestorsChristiaan Prins Tristan van StrienDirector of Global Communication Global Director of Investor RelationsMarlie Paauw Lennart Scholtus / Chris SteynCorporate Communications Lead Investor Relations Manager / Senior AnalystE-mail: [email protected] E-mail: [email protected] Tel: +31-20-5239355 Tel: +31-20-5239590 Regulatory information
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
HEINEKEN is the world's most international brewer. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through "Brew a Better World", sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on our Company's website and follow us on LinkedIn and Instagram.

HNV_SBB 2025_Weekly update_29-Sep-2025

, /PRNewswire/ -- Escalade, Inc. (NASDAQ: ESCA), a leader in archery, sporting goods and indoor/outdoor recreation equipment, today announced the acquisition of the Gold Tip business from Revelyst Inc., a collective of world-class maker brands that design and manufacture sports technology and outdoor gear. Founded in 1989, Gold Tip is a leading manufacturer of products for target archery and bow and crossbow hunting. Known as a pioneer of modern archery technology and a leading maker of innovative, durable, and accurate carbon arrows, Gold Tip also produces the Bee Stinger line of premium bow stabilizers.

Having participated in the archery market for nearly one hundred years, Escalade recognizes the strength of the Gold Tip and Bee Stinger brands and their enduring connection to archery and bowhunting enthusiasts. The acquisition presents a significant opportunity to further expand Escalade's presence in the archery market with the addition of precision carbon arrows and premium stabilizers. Gold Tip and Bee Stinger complement Escalade's portfolio of leading archery brands which includes Bear Archery®, Trophy Ridge®, and Cajun Bowfishing®. 

"We have been committed to archery for generations and a proud steward of Fred Bear's incredible legacy for over 20 years. The archery and bowhunting markets continue to be a strategic priority for Escalade. Adding Gold Tip and Bee Stinger to our archery family will further strengthen our market position and expand our opportunities. We look forward to investing in Gold Tip and Bee Stinger to further accelerate product innovation and to build on both brands' past success," said Escalade's CEO Armin Boehm.

Eric Nyman, CEO of Revelyst, commented: "The sale of Gold Tip and Bee Stinger allows us to further concentrate our focus on our key categories and brands while accelerating our investments in sports technology and gear. Escalade is a natural home and owner for the Gold Tip and Bee Stinger business, and I'm thrilled these brands will be in their capable hands."

Gold Tip and Bee Stinger will join Escalade's archery portfolio, which is led by Jon Lené, President of Bear Archery.

"This is an exciting new chapter with Gold Tip and Bee Stinger joining our family. We are realizing our strategic goal of providing a complete and market leading range of archery and bowhunting products to better serve our loyal dealers, distributors, and retailers. The addition of these two leading brands will expand our team's commitment to offer the best and most innovative products backed by superior customer service, distribution, and sales and marketing expertise," said Jon Lené.

ABOUT ESCALADE

Founded in 1922, and headquartered in Evansville, Indiana, Escalade designs, manufactures, and sells archery, sporting goods, fitness, and indoor/outdoor recreation equipment. Our mission is to connect family and friends, create lasting memories, and play life to the fullest. Leaders in our respective categories, Escalade's distinct and acclaimed brands include Goalrilla™ in-ground basketball hoops; STIGA® tennis tables and accessories; Bear® Archery and archery equipment; Brunswick Billiards® tables and accessories; Accudart® darting; ONIX® pickleball; Lifeline® fitness products; and RAVE Sports® water recreation products. Escalade's products are available online and through leading retailers nationwide. For more information about Escalade's diverse and prominent brand portfolio, history, financials, and governance, please visit www.escaladeinc.com.

ABOUT REVELYST

Revelyst Inc. is a collective of world-class maker brands that design and manufacture sports technology and outdoor gear. Our category-defining brands leverage meticulous craftsmanship and cross-collaboration to pursue new innovations that redefine what is humanly possible in the outdoors. Portfolio brands include Foresight Sports, Bushnell Golf, Fox, Bell, Giro, CamelBak, Bushnell, Simms Fishing and more. For more information, visit our website at www.revelyst.com.

FORWARD-LOOKING STATEMENTS 

This report contains forward-looking statements relating to present or future trends or factors that are subject to risks and uncertainties. These risks include, but are not limited to, Escalade's ability to successfully achieve the anticipated results of strategic acquisitions, including the integration of the operations of acquired assets and businesses, the impact of competitive products and pricing, product demand and market acceptance, and other risks detailed from time to time in Escalade's filings with the Securities and Exchange Commission. Escalade undertakes no obligation to release revisions to these forward-looking statements after the date of this report.

INVESTOR RELATIONS CONTACTS

Escalade Contact:

Patrick Griffin

Phone: 812-467-1358 

Email: [email protected]

Revelyst Contact:

Eric Smith

Phone: 720-772-0877

Email: [email protected]

SOURCE Escalade, Incorporated

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

LAS VEGAS, NV / ACCESS Newswire / September 29, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, announced today that it has entered an agreement with Automated Technical Services to design and build a commercial-scale Mushroom Accelerator. This scaled-up system will produce Hypha's proprietary mushroom-based ingredients for sale to nutraceutical manufacturers worldwide.